Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice

Thalidomide's reported ability to inhibit angiogenesis has led to clinical trials determining its effectiveness in combating various types of cancer. This study explored thalidomide's antitumorigenic potential when administered alone and in combination with cisplatin to DBA2/J mice whose t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruddy, Jean Marie B., Majumdar, Shyamal K.
Formato: Texto
Lenguaje:English
Publicado: 2002
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC139116/
https://www.ncbi.nlm.nih.gov/pubmed/12488594
http://dx.doi.org/10.1155/S1110724302000359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC139116/
https://www.ncbi.nlm.nih.gov/pubmed/12488594
http://dx.doi.org/10.1155/S1110724302000359

Ejemplares similares